175 related articles for article (PubMed ID: 36111167)
21. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
22. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
24. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
25. Hsa_circ_0004296 inhibits metastasis of prostate cancer by interacting with EIF4A3 to prevent nuclear export of ETS1 mRNA.
Mao S; Zhang W; Yang F; Guo Y; Wang H; Wu Y; Wang R; Maskey N; Zheng Z; Li C; Ma W; Zhang J; Yan Y; Yao X
J Exp Clin Cancer Res; 2021 Oct; 40(1):336. PubMed ID: 34696782
[TBL] [Abstract][Full Text] [Related]
26. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.
Deng M; Zeng C; Lu X; He X; Zhang R; Qiu Q; Zheng G; Jia X; Liu H; He Z
Cancer Lett; 2017 Sep; 403():175-185. PubMed ID: 28634044
[TBL] [Abstract][Full Text] [Related]
27. Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.
Ruppender N; Larson S; Lakely B; Kollath L; Brown L; Coleman I; Coleman R; Nguyen H; Nelson PS; Corey E; Snyder LA; Vessella RL; Morrissey C; Lam HM
PLoS One; 2015; 10(6):e0130565. PubMed ID: 26090669
[TBL] [Abstract][Full Text] [Related]
28. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
Lin ZY; Chen G; Zhang YQ; He HC; Liang YX; Ye JH; Liang YK; Mo RJ; Lu JM; Zhuo YJ; Zheng Y; Jiang FN; Han ZD; Wu SL; Zhong WD; Wu CL
Mol Cancer; 2017 Feb; 16(1):48. PubMed ID: 28241827
[TBL] [Abstract][Full Text] [Related]
30. MiR-29c suppresses cell invasion and migration by directly targeting CDK6 in gastric carcinoma.
Jiang H; Liu ZN; Cheng XH; Zhang YF; Dai X; Bao GM; Zhou LB
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7920-7928. PubMed ID: 31599417
[TBL] [Abstract][Full Text] [Related]
31. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
Kiener M; Chen L; Krebs M; Grosjean J; Klima I; Kalogirou C; Riedmiller H; Kneitz B; Thalmann GN; Snaar-Jagalska E; Spahn M; Kruithof-de Julio M; Zoni E
BMC Cancer; 2019 Jun; 19(1):627. PubMed ID: 31238903
[TBL] [Abstract][Full Text] [Related]
32. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of lncRNA-UCA1 inhibits cell viability and migration of human glioma cells by miR-193a-mediated downregulation of CDK6.
Xin H; Liu N; Xu X; Zhang J; Li Y; Ma Y; Li G; Liang J
J Cell Biochem; 2019 Sep; 120(9):15157-15169. PubMed ID: 31111564
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.
Ito K; Maruyama Z; Sakai A; Izumi S; Moriishi T; Yoshida CA; Miyazaki T; Komori H; Takada K; Kawaguchi H; Komori T
Oncogene; 2014 Apr; 33(14):1862-71. PubMed ID: 23624920
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA nuclear enriched abundant transcript 1 impacts cell proliferation, invasion, and migration of glioma through regulating miR-139-5p/ CDK6.
Wu DM; Wang S; Wen X; Han XR; Wang YJ; Fan SH; Zhang ZF; Shan Q; Lu J; Zheng YL
J Cell Physiol; 2019 May; 234(5):5972-5987. PubMed ID: 30515782
[TBL] [Abstract][Full Text] [Related]
36. LINC00704 contributes to the proliferation and accelerates the cell cycle of nasopharyngeal carcinoma cells via regulating ETS1/CDK6 axis.
Wang Y; Tan QY; Shen Y; Liu CY; Huang T; Huai D; Dai J
Kaohsiung J Med Sci; 2022 Apr; 38(4):312-320. PubMed ID: 34989116
[TBL] [Abstract][Full Text] [Related]
37. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.
Cai C; Chen QB; Han ZD; Zhang YQ; He HC; Chen JH; Chen YR; Yang SB; Wu YD; Zeng YR; Qin GQ; Liang YX; Dai QS; Jiang FN; Wu SL; Zeng GH; Zhong WD; Wu CL
Clin Cancer Res; 2015 Nov; 21(21):4922-34. PubMed ID: 26080838
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA CRNDE promotes malignant progression of hepatocellular carcinoma through the miR-33a-5p/CDK6 axis.
Lin C; Xiang Y; Sheng J; Liu S; Cui M; Zhang X
J Physiol Biochem; 2020 Aug; 76(3):469-481. PubMed ID: 32621257
[TBL] [Abstract][Full Text] [Related]
39. PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.
Lv C; Fu S; Dong Q; Yu Z; Zhang G; Kong C; Fu C; Zeng Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):24. PubMed ID: 30658679
[TBL] [Abstract][Full Text] [Related]
40. miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer.
Chen R; Sheng L; Zhang HJ; Ji M; Qian WQ
J Cell Mol Med; 2018 Mar; 22(3):1855-1863. PubMed ID: 29363862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
